PMID: 25866791 View source Seiwerth S, et al
Dihexa (10mg) / Tesofensine (250mcg) / BPC-157 (125mcg) Tri-Compound Oral Research Formulation x 60 Tablets Oral solid-form research compound formulated for controlled analytical and investigational applications
Its proposed mechanisms are complex and multifaceted, involving interactions with the nitric oxide (NO) system, influence on growth factor expression (like Vascular Endothelial Growth Factor or VEGF), and modulation of cellular pathways related to tissue repair
[10] Histologically, treatment increased myelinated axons and vessel density in the ischemic boundary zone and augmented remyelination, associated with more oligodendrocyte progenitor cells and myelinating oligodendrocytes
USP Standards: The United States Pharmacopeia (USP) sets monographs for various pharmaceutical ingredients and preparations, including water for injection
Kong C, Ni X, Wang Y, Zhang A, Zhang Y, Lin F, et al